Pitfalls in new artemisinin-containing antimalarial drug development

Area of Science:

• Tropical medicine
• Pharmacology
• Public health

Background:

• Artemisinin combination therapy (ACT) is a cornerstone for malaria elimination efforts in tropical regions.
• Increased ACT consumption raises concerns about future drug availability and potential decreases in efficacy.
• Ensuring a robust supply of high-quality ACT drugs is critical for ongoing malaria control programs.

Purpose of the Study:

• To highlight the urgent need to strengthen the ACT supply chain, from crop production to drug accreditation.
• To emphasize the importance of validating new ACT formulations through bioequivalence studies.
• To underscore the necessity for national malaria control teams to rigorously review new drug dossiers.

Main Methods:

• Review of current challenges in ACT production and supply chain management.
• Analysis of reported decreases in ACT efficacy.
• Discussion of regulatory requirements for new drug formulations, including bioequivalence studies.

Main Results:

• ACT availability may be threatened by increased demand and potential efficacy issues.
• The process from artemisia cultivation to new ACT accreditation requires significant enhancement.
• New suppliers and formulations present opportunities but necessitate stringent validation.

Conclusions:

• Strengthening the entire ACT supply chain is paramount for sustained malaria elimination.
• Rigorous scrutiny of new ACT formulations and their bioequivalence data is essential for national malaria control programs.
• Proactive measures are needed to ensure a consistent supply of effective malaria treatments.